47 related articles for article (PubMed ID: 15221786)
1. Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma.
Wang Y; Kringen P; Kristensen GB; Holm R; Baekelandt MM; Olivier M; Skomedal H; Hainaut P; Tropé CG; Abeler VM; Nesland JM; Børresen-Dale AL; Helland A
Hum Mutat; 2004 Jul; 24(1):21-34. PubMed ID: 15221786
[TBL] [Abstract][Full Text] [Related]
2. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; ; DeFazio A; Kaufmann S; Churchman M; Gourley C; Stephens AN; Meagher NS; Ramus SJ; Antill YC; Campbell I; Scott CL; Köbel M; Gorringe KL;
Mod Pathol; 2021 Jan; 34(1):194-206. PubMed ID: 32724153
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical correlates of TP53 somatic mutations in cancer.
Murnyák B; Hortobágyi T
Oncotarget; 2016 Oct; 7(40):64910-64920. PubMed ID: 27626311
[TBL] [Abstract][Full Text] [Related]
4. Identification of Genetic Variants in Exon 4 of TP53 in Lung Carcinoma and in Silico Prediction of Their Significance.
Prasad R; Sharma K; Bhutani K; Prasad S; Manhas S; Kishan J
Indian J Clin Biochem; 2024 Apr; 39(2):276-282. PubMed ID: 38577139
[TBL] [Abstract][Full Text] [Related]
5. Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene.
Doffe F; Carbonnier V; Tissier M; Leroy B; Martins I; Mattsson JSM; Micke P; Pavlova S; Pospisilova S; Smardova J; Joerger AC; Wiman KG; Kroemer G; Soussi T
Cell Death Differ; 2021 May; 28(5):1477-1492. PubMed ID: 33257846
[TBL] [Abstract][Full Text] [Related]
6.
Vieira JO; Pesquero JB; Nazário ACP
Breast Care (Basel); 2024 Apr; 19(2):96-105. PubMed ID: 38765899
[TBL] [Abstract][Full Text] [Related]
7.
Saif R; Awan AR; Lyons L; Gandolfi B; Tayyab M; Ellahi Babar M; Khalid Mehmood A; Ullah Z; Wasim M
Iran J Biotechnol; 2016 Sep; 14(3):202-212. PubMed ID: 28959337
[TBL] [Abstract][Full Text] [Related]
8. p53 polymorphisms: cancer implications.
Whibley C; Pharoah PD; Hollstein M
Nat Rev Cancer; 2009 Feb; 9(2):95-107. PubMed ID: 19165225
[TBL] [Abstract][Full Text] [Related]
9. Genetic Influences in Breast Cancer Drug Resistance.
Daniyal A; Santoso I; Gunawan NHP; Barliana MI; Abdulah R
Breast Cancer (Dove Med Press); 2021; 13():59-85. PubMed ID: 33603458
[TBL] [Abstract][Full Text] [Related]
10. A Case-Control Study of TP53 R72P Polymorphism in the Breast Cancer Patients of Ethnic Kashmiri Population.
Syeed N; Sameer AS; Abdullah S; Husain SA; Siddiqi MA
World J Oncol; 2010 Dec; 1(6):236-241. PubMed ID: 29147214
[TBL] [Abstract][Full Text] [Related]
11. A Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to Tumorigenesis.
Longacre M; Snyder NA; Housman G; Leary M; Lapinska K; Heerboth S; Willbanks A; Sarkar S
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213343
[TBL] [Abstract][Full Text] [Related]
12. Mutation Analysis of TP53 Tumor Suppressor Gene in Colorectal Cancer in Patients from Iran (Kerman Province).
Nejad AL; Yaghoobi MM
Iran J Basic Med Sci; 2012 Jan; 15(1):683-90. PubMed ID: 23492839
[TBL] [Abstract][Full Text] [Related]
13. High levels of genomic aberrations in serous ovarian cancers are associated with better survival.
Baumbusch LO; Helland Å; Wang Y; Liestøl K; Schaner ME; Holm R; Etemadmoghadam D; Alsop K; Brown P; ; Mitchell G; Fereday S; DeFazio A; Bowtell DD; Kristensen GB; Lingjærde OC; Børresen-Dale AL
PLoS One; 2013; 8(1):e54356. PubMed ID: 23372714
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of the TP53 Arg72Pro single-nucleotide polymorphism and susceptibility to medulloblastoma in a cohort of Brazilian patients.
Carvalho RM; Pinto GR; Yoshioka FK; Lima PD; Souza CR; Guimarães AC; Lamarão LM; Rey JA; Burbano RR
J Neurooncol; 2012 Oct; 110(1):49-57. PubMed ID: 22886512
[TBL] [Abstract][Full Text] [Related]
15. Prognostic biomarkers in ovarian cancer.
Huang J; Hu W; Sood AK
Cancer Biomark; 2010-2011; 8(4-5):231-51. PubMed ID: 22045356
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk.
Shen SQ; Jiang DK; Liu GY; Chen F; Yu L
Mol Biol Rep; 2012 Apr; 39(4):4683-90. PubMed ID: 21952824
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier M; Hollstein M; Hainaut P
Cold Spring Harb Perspect Biol; 2010 Jan; 2(1):a001008. PubMed ID: 20182602
[TBL] [Abstract][Full Text] [Related]
18. Association study between P53 and P73 gene polymorphisms and the sporadic late-onset form of Alzheimer's disease.
Scacchi R; Gambina G; Moretto G; Corbo RM
J Neural Transm (Vienna); 2009 Sep; 116(9):1179-84. PubMed ID: 19657586
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment.
Hrstka R; Coates PJ; Vojtesek B
J Cell Mol Med; 2009 Mar; 13(3):440-53. PubMed ID: 19379143
[TBL] [Abstract][Full Text] [Related]
20. Germline polymorphism of cancer susceptibility genes in gynecologic cancer.
Ueda M; Toji E; Nunobiki O; Izuma S; Okamoto Y; Torii K; Noda S
Hum Cell; 2008 Nov; 21(4):95-104. PubMed ID: 19067761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
